Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to assess [18F]MNI-777 PET imaging as a tool to detect tau
pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy,
including: Alzheimer's Disease (AD),Parkinson's disease (PD) Progressive Supranuclear Palsy
(PSP), chronic traumatic encephalopathy (CTE) and Frontal Temporal Dementia (FTD) and age-
and gender-matched healthy subjects.